https://sparkcures.com 2019-05-01 monthly 0.9 https://sparkcures.com/help/about-us 2019-05-01 monthly 0.5 https://sparkcures.com/clinical-trials 2019-05-20 weeky 0.5 https://sparkcures.com/clinical-trials/view/7/uark-2008-01-total-therapy-4-a-phase-iii-trial-for-low-risk-myeloma-nct00734877 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/11/tandem-auto-stem-cell-transplant-with-melphalan-followed-by-melphalan-and-bortezomib-in-patients-with-multiple-myeloma-nct01241708 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/22/bortezomib-or-carfilzomib-with-lenalidomide-and-dexamethasone-in-treating-patients-with-newly-diagnosed-multiple-myeloma-nct01863550 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/57/a-safety-and-efficacy-study-of-carfilzomib-and-pomalidomide-with-dexamethasone-in-patients-with-relapsed-or-refractory-multiple-myeloma-nct01464034 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/74/cord-blood-natural-killer-cells-for-myeloma-nct01729091 2018-11-07 weeky 1.0 https://sparkcures.com/clinical-trials/view/81/ixazomib-cyclophosphamide-and-dexamethasone-in-treating-patients-with-previously-untreated-symptomatic-multiple-myeloma-nct01864018 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/93/carfilzomib-with-bendamustine-and-dexamethasone-in-multiple-myeloma-nct02002598 2018-04-24 weeky 1.0 https://sparkcures.com/clinical-trials/view/101/donor-stem-cell-transplant-in-treating-patients-with-previously-treated-lymphoma-multiple-myeloma-or-chronic-lymphocytic-leukemia-nct00612716 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/105/umbilical-cord-blood-transplant-cyclophosphamide-fludarabine-phosphate-and-total-body-irradiation-in-treating-patients-with-hematologic-disease-nct00719888 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/119/hla-compatible-related-or-unrelated-donors-with-cd34-enriched-t-cell-depleted-peripheral-blood-stem-cells-isolated-by-the-clinimacs-system-in-the-treatment-of-patients-with-hematologic-malignancies-nct01119066 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/127/sirolimus-cyclosporine-and-mycophenolate-mofetil-in-preventing-graft-versus-host-disease-in-treating-patients-with-hematologic-malignancies-undergoing-donor-peripheral-blood-stem-cell-transplant-nct01251575 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/133/a-two-step-approach-to-reduced-intensity-bone-marrow-transplant-for-patients-with-hematological-malignancies-nct01384513 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/137/proteasome-inhibitor-mln9708-in-treating-patients-with-relapsed-multiple-myeloma-that-is-not-refractory-to-bortezomib-nct01415882 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/141/auto-transplant-high-dose-melphalan-vs-high-dose-melphalan-bortezomib-in-pts-with-multiple-myeloma-age-65-years-or-older-nct01453088 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/156/carfilzomib-lenalidomide-and-dexamethasone-for-smoldering-multiple-myeloma-nct01572480 2019-05-07 weeky 1.0 https://sparkcures.com/clinical-trials/view/827/timed-sequential-busulfan-and-post-transplant-cyclophosphamide-for-allogeneic-transplantation-nct02861417 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/170/reduced-intensity-conditioning-before-donor-stem-cell-transplant-in-treating-patients-with-high-risk-hematologic-malignancies-nct01760655 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/171/cord-blood-transplant-nct01768845 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/865/a-safety-study-to-determine-dose-and-tolerability-of-cc-220-monotherapy-and-in-combination-with-dexamethasone-in-subjects-with-relapsed-and-refractory-multiple-myeloma-nct02773030 2019-02-26 weeky 1.0 https://sparkcures.com/clinical-trials/view/222/an-investigational-immuno-therapy-study-to-determine-the-safety-and-effectiveness-of-nivolumab-and-daratumumab-in-patients-with-multiple-myeloma-nct01592370 2019-02-05 weeky 1.0 https://sparkcures.com/clinical-trials/view/260/bone-marrow-and-kidney-transplant-for-patients-with-chronic-kidney-disease-and-blood-disorders-nct01758042 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/262/nct01810588targeting-the-inherited-paternal-antigen-ipa-and-matching-for-the-non-inherited-maternal-antigen-nima-for-haplo-cord-transplantation-nct01810588 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/279/vandetanib-with-everolimus-nct01582191 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/284/bevacizumab-temsirolimus-valproic-acid-cetuximab-nct01552434 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/358/safety-study-of-unlicensed-investigational-cord-blood-units-manufactured-by-the-ncbp-for-unrelated-transplantation-nct01656603 2018-11-07 weeky 1.0 https://sparkcures.com/clinical-trials/view/386/umbilical-cord-blood-transplantation-using-a-myeloablative-preparative-regimen-for-hematological-diseases-nct01962636 2017-10-09 weeky 1.0 https://sparkcures.com/clinical-trials/view/449/carfilzomib-pomalidomide-and-dexamethasone-in-treating-patients-with-relapsed-or-refractory-multiple-myeloma-nct01665794 2018-04-24 weeky 1.0 https://sparkcures.com/clinical-trials/view/472/pomalidomide-and-dexamethasone-with-or-without-ixazomib-in-treating-patients-with-relapsed-multiple-myeloma-nct02004275 2019-05-14 weeky 1.0 https://sparkcures.com/clinical-trials/view/849/study-of-initial-treatment-with-elotuzumab-carfilzomib-lenalidomide-and-dexamethasone-in-multiple-myeloma-nct02969837 2018-03-19 weeky 1.0 https://sparkcures.com/clinical-trials/view/510/nct02101944 2019-04-14 weeky 1.0 https://sparkcures.com/clinical-trials/view/659/a-study-of-apto-253-hcl-in-patients-with-relapsed-or-refractory-hematologic-malignancies-nct02267863 2019-04-21 weeky 1.0 https://sparkcures.com/clinical-trials/view/634/a-phase-ii-trial-of-oncolytic-virotherapy-by-systemic-administration-of-edmonston-strain-of-measles-virus-nct02192775 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/774/study-of-incb053914-in-subjects-with-advanced-malignancies-nct02587598 2018-11-20 weeky 1.0 https://sparkcures.com/clinical-trials/view/775/a-dose-escalation-study-of-onc201-administered-every-one-two-or-three-weeks-in-advanced-solid-tumors-and-multiple-myeloma-nct02609230 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/650/phase-ii-study-of-ird-ixazomib-lenalidomide-dexamethasone-post-autologous-stem-cell-transplantation-followed-by-maintenance-ixazomib-or-lenalidomide-for-multiple-myeloma-nct02253316 2019-01-11 weeky 1.0 https://sparkcures.com/clinical-trials/view/690/natural-killer-nk-cells-in-cord-blood-transplantation-nct01619761 2018-02-16 weeky 1.0 https://sparkcures.com/clinical-trials/view/695/tumor-associated-antigen-specific-cytotoxic-t-lymphocytes-for-multiple-myeloma-nct02291848 2018-01-07 weeky 1.0 https://sparkcures.com/clinical-trials/view/701/svn53-67-m57-klh-peptide-vaccine-in-treating-patients-with-newly-diagnosed-multiple-myeloma-receiving-lenalidomide-maintenance-therapy-nct02334865 2019-02-26 weeky 1.0 https://sparkcures.com/clinical-trials/view/773/reduced-intensity-chemotherapy-and-radiation-therapy-before-donor-stem-cell-transplant-in-treating-patients-with-hematologic-malignancies-nct02566304 2018-05-22 weeky 1.0 https://sparkcures.com/clinical-trials/view/720/lenalidomide-with-or-without-ixazomib-citrate-and-dexamethasone-in-treating-patients-with-residual-multiple-myeloma-after-donor-stem-cell-transplant-nct02389517 2019-02-14 weeky 1.0 https://sparkcures.com/clinical-trials/view/728/a-study-of-atezolizumab-anti-programmed-death-ligand-1-pd-l1-antibody-alone-or-in-combination-with-an-immunomodulatory-drug-and-or-daratumumab-in-participants-with-multiple-myeloma-mm-nct02431208 2019-04-25 weeky 1.0 https://sparkcures.com/clinical-trials/view/872/elotuzumab-lenalidomide-and-dexamethasone-erd-in-the-induction-consolidation-and-maintenance-treatment-of-transplant-eligible-newly-diagnosed-multiple-myeloma-patients-nct02843074 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/863/mdm2-inhibitor-amg-232-carfilzomib-lenalidomide-and-dexamethasone-in-treating-patients-with-relapsed-or-refractory-multiple-myeloma-nct03031730 2018-07-24 weeky 1.0 https://sparkcures.com/clinical-trials/view/738/phase-1b-2-study-of-selinexor-kpt-330-in-combination-w-backbone-treatments-for-relapsed-refractory-multiple-myeloma-stomp-nct02343042 2018-10-18 weeky 1.0 https://sparkcures.com/clinical-trials/view/842/study-on-the-effect-of-ibrutinib-on-high-risk-smoldering-multiple-myeloma-patients-nct02943473 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/746/panobinostat-combined-with-high-dose-gemcitabinebusulfanmelphalan-with-autologous-stem-cell-transplant-for-patients-with-refractoryrelapsed-myeloma-nct02506959 2018-11-01 weeky 1.0 https://sparkcures.com/clinical-trials/view/848/trial-of-isatuximab-sar650984-in-patients-with-intermediate-and-high-risk-smoldering-multiple-myeloma-nct02960555 2018-11-10 weeky 1.0 https://sparkcures.com/clinical-trials/view/747/combination-chemotherapy-and-donor-stem-cell-transplant-followed-by-ixazomib-citrate-maintenance-therapy-in-treating-patients-with-relapsed-high-risk-multiple-myeloma-nct02504359 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/750/a-study-to-evaluate-the-safety-and-pharmacokinetics-of-sar650984-in-patients-with-multiple-myeloma-nct02514668 2019-02-12 weeky 1.0 https://sparkcures.com/clinical-trials/view/753/pomalidomide-ixazomib-citrate-and-dexamethasone-in-treating-patients-with-previously-treated-multiple-myeloma-or-plasma-cell-leukemia-nct02547662 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/755/clinical-study-of-cwp232291-in-relapsed-or-refractory-myeloma-patients-nct02426723 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/756/dose-escalation-study-of-i-131-clr1404-in-patients-with-relapsed-or-refractory-multiple-myeloma-nct02278315 2019-05-17 weeky 1.0 https://sparkcures.com/clinical-trials/view/759/study-of-precursor-hematological-malignancies-to-assess-the-relationship-between-molecular-events-of-progression-and-clinical-outcome-pcrowd-nct02269592 2018-11-07 weeky 1.0 https://sparkcures.com/clinical-trials/view/761/ohio-state-university-multiple-myeloma-and-amyloidosis-data-registry-and-sample-resource-nct01408225 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/763/study-of-edo-s101-a-first-in-class-alkylating-hdaci-fusion-molecule-in-relapsedrefractory-hematologic-malignancies-nct02576496 2019-04-21 weeky 1.0 https://sparkcures.com/clinical-trials/view/837/mmrf-molecular-profiling-protocol-nct02884102 2019-03-22 weeky 1.0 https://sparkcures.com/clinical-trials/view/769/allogeneic-stem-cell-transplantationin-relapsed-hematological-malignancy-early-gvhd-prophylaxis-nct02593123 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/776/phase-1-2-trial-of-idasanutlin-in-combination-with-ixazomib-and-dexamethasone-in-patients-with-17p-deleted-relapsed-multiple-myeloma-nct02633059 2018-07-13 weeky 1.0 https://sparkcures.com/clinical-trials/view/777/alternating-ixazomib-citrate-and-lenalidomide-as-maintenance-therapy-after-stem-cell-transplant-in-treating-patients-with-multiple-myeloma-nct02619682 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/828/oral-onc201-in-relapsedrefractory-multiple-myeloma-nct02863991 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/784/sl-401-in-combination-with-pomalidomide-and-dexamethasone-in-relapsed-or-relapsed-and-refractory-multiple-myeloma-nct02661022 2019-03-18 weeky 1.0 https://sparkcures.com/clinical-trials/view/785/allogeneic-hematopoietic-stem-cell-transplantation-using-reduced-intensity-conditioning-ric-for-the-treatment-of-hematological-diseases-nct02661035 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/787/trial-of-carfilzomib-lenalidomide-dexamethasone-versus-lenalidomide-alone-after-stem-cell-transplant-for-multiple-myeloma-nct02659293 2018-02-13 weeky 1.0 https://sparkcures.com/clinical-trials/view/794/uark-2012-02-trial-for-high-risk-myeloma-evaluating-accelerating-and-sustaining-complete-remission-nct02128230 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/801/tapur-testing-the-use-of-food-and-drug-administration-fda-approved-drugs-that-target-a-specific-abnormality-in-a-tumor-gene-in-people-with-advanced-stage-cancer-nct02693535 2018-04-24 weeky 1.0 https://sparkcures.com/clinical-trials/view/802/panobinostat-lbh589-multiple-myeloma-autologous-hematopoietic-cell-transplantation-hct-nct02722941 2018-10-11 weeky 1.0 https://sparkcures.com/clinical-trials/view/803/ucb-transplant-for-hematological-diseases-using-a-non-myeloablative-prep-nct02722668 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/809/abc294640-in-refractory-relapsed-multiple-myeloma-nct02757326 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/811/a-diagnostic-screening-trial-seeking-al-amyloidosis-very-early-nct02741999 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/812/ixazomib-and-dexamethasone-versus-ixazomib-dexamethasone-and-lenalidomide-randomized-with-nfkb2-rearrangement-nct02765854 2018-09-05 weeky 1.0 https://sparkcures.com/clinical-trials/view/813/selinexor-plus-high-dose-melphalan-hdm-before-autologous-hematopoietic-cell-transplantation-for-multiple-myeloma-nct02780609 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/819/insight-the-insight-mm-study-a-global-prospective-non-interventional-observational-study-of-presentation-treatment-patterns-and-outcomes-in-multiple-myeloma-nct02761187 2019-03-18 weeky 1.0 https://sparkcures.com/clinical-trials/view/820/a-study-to-test-the-combination-of-selinexor-kpt-330-ixazomib-and-dexamethasone-in-patients-with-myeloma-nct02831686 0208-08-24 weeky 1.0 https://sparkcures.com/clinical-trials/view/821/panobinostatbortezomibdexamethasone-in-relapsed-or-relapsed-and-refractory-multiple-myeloma-nct02654990 2018-12-26 weeky 1.0 https://sparkcures.com/clinical-trials/view/835/a-study-of-two-investigational-drugs-including-pvx-410-a-multi-peptide-cancer-vaccine-and-citarinostat-a-histone-deacetylase-inhibitor-hdac-lenalidomide-for-patients-with-moderate-or-high-risk-of-progression-smoldering-multiple-myeloma-nct02886065 2019-03-29 weeky 1.0 https://sparkcures.com/clinical-trials/view/824/a-study-of-denosumab-in-multiple-myeloma-patients-with-renal-insufficiency-nct02833610 2018-04-24 weeky 1.0 https://sparkcures.com/clinical-trials/view/831/ixazomib-with-pomalidomide-clarithromycin-and-dexamethasone-in-treating-patients-with-multiple-myeloma-nct02542657 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/838/study-of-captisol-enabled-melphalan-and-pharmacokinetics-for-patients-with-multiple-myeloma-or-light-chain-amyloidosis-that-are-receiving-an-autologous-transplant-nct02909036 2018-08-30 weeky 1.0 https://sparkcures.com/clinical-trials/view/840/trial-of-combination-of-ixazomib-and-lenalidomide-and-dexamethasone-in-smoldering-multiple-myeloma-nct02916771 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/845/amg-176-first-in-human-trial-in-subjects-with-relapsed-or-refractory-multiple-myeloma-nct02675452 2019-03-01 weeky 1.0 https://sparkcures.com/clinical-trials/view/850/a-study-of-melflufen-in-combination-with-dexamethasone-in-relapsed-refractory-multiple-myeloma-patients-nct02963493 2018-11-28 weeky 1.0 https://sparkcures.com/clinical-trials/view/853/exploratory-trial-to-estimate-proportion-of-patients-with-tumor-cell-contaminated-leukapheresis-products-with-and-without-bortezomib-with-in-vivo-purging-multiple-myeloma-mm-nct02703779 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/854/lintuzumab-ac225-for-refractory-multiple-myeloma-nct02998047 2018-12-26 weeky 1.0 https://sparkcures.com/clinical-trials/view/855/phase-i-study-of-mik665-a-mcl-1-inhibitor-in-patients-with-refractory-or-relapsed-lymphoma-or-multiple-myeloma-nct02992483 2018-06-07 weeky 1.0 https://sparkcures.com/clinical-trials/view/858/ixazomib-citrate-lenalidomide-dexamethasone-and-daratumumab-in-treating-patients-with-newly-diagnosed-multiple-myeloma-nct03012880 2019-02-26 weeky 1.0 https://sparkcures.com/clinical-trials/view/860/elotuzumab-pomalidomide-dexamethasone-elo-pom-dex-with-second-autologous-stem-cell-transplantation-for-relapsed-multiple-myeloma-nct03030261 2017-12-04 weeky 1.0 https://sparkcures.com/clinical-trials/view/864/a-dose-escalation-study-to-investigate-the-safety-pharmacokinetics-pk-pharmacodynamics-pd-and-clinical-activity-of-gsk525762-in-subjects-with-relapsed-refractory-hematologic-malignancies-nct01943851 2018-02-15 weeky 1.0 https://sparkcures.com/clinical-trials/view/871/an-open-label-multicenter-phase-2-study-of-clr-131-in-patients-with-relapsed-or-refractory-rr-select-b-cell-malignancies-clover-1-nct02952508 2019-05-17 weeky 1.0 https://sparkcures.com/clinical-trials/view/873/combination-study-for-high-risk-multiple-myeloma-patients-nct03104270 2018-04-14 weeky 1.0 https://sparkcures.com/clinical-trials/view/874/high-dose-chemotherapy-using-beeam-for-autologous-transplant-in-multiple-myeloma-nct02416206 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/875/study-of-bromodomain-and-extra-terminal-protein-bet-inhibitor-ro6870810-as-mono-and-combination-therapy-in-advanced-multiple-myeloma-nct03068351 2018-11-13 weeky 1.0 https://sparkcures.com/clinical-trials/view/876/a-multiple-ascending-dose-study-of-medi7247-in-patients-with-selected-relapsedrefractory-hematological-malignancies-nct03106428 2019-01-21 weeky 1.0 https://sparkcures.com/clinical-trials/view/877/prospective-observational-study-of-clinical-and-genomic-predictors-of-progression-to-myeloma-in-asymptomatic-monoclonal-gammopathies-nct02726750 2017-10-26 weeky 1.0 https://sparkcures.com/clinical-trials/view/878/dose-escalation-study-of-jnj-64007957-a-humanized-bcma-cd3-duobody-antibody-in-participants-with-relapsed-or-refractory-multiple-myeloma-nct03145181 2018-12-26 weeky 1.0 https://sparkcures.com/clinical-trials/view/880/a-study-of-dabrafenib-andor-trametinib-in-patients-with-relapsed-andor-refractory-multiple-myeloma-nct03091257 2019-04-16 weeky 1.0 https://sparkcures.com/clinical-trials/view/882/weekly-70-mgm2-carfilzomib-for-multiple-myeloma-patients-refractory-to-27-mgm2-carfilzomib-nct02294357 2018-03-19 weeky 1.0 https://sparkcures.com/clinical-trials/view/883/a-phase-1-study-of-ruxolitinib-steroids-and-lenalidomide-for-relapsedrefractory-multiple-myeloma-rrmm-patients-nct03110822 2018-12-11 weeky 1.0 https://sparkcures.com/clinical-trials/view/884/pomalidomide-for-lenalidomide-for-failures-nct02188368 2018-03-19 weeky 1.0 https://sparkcures.com/clinical-trials/view/885/phase-1b-study-evaluating-opomd-in-relapsed-or-refractory-multiple-myeloma-nct02939183 2018-05-08 weeky 1.0 https://sparkcures.com/clinical-trials/view/887/a-study-of-melflufen-dex-or-pomalidomide-dex-for-rrmm-patients-refractory-to-lenalidomide-nct03151811 2019-02-20 weeky 1.0 https://sparkcures.com/clinical-trials/view/888/ny-eso-1c259t-alone-and-in-combination-with-pembrolizumab-for-multiple-myeloma-nct03168438 2018-10-11 weeky 1.0 https://sparkcures.com/clinical-trials/view/894/tew-7197-in-combination-w-pomalidomide-in-relapsed-or-relapsed-and-refractory-multiple-myeloma-nct03143985 2019-02-08 weeky 1.0 https://sparkcures.com/clinical-trials/view/895/an-efficacy-study-comparing-oral-ixazomibdexamethasone-and-oral-pomalidomidedexamethasone-in-relapsed-andor-refractory-multiple-myeloma-nct03170882 2018-07-10 weeky 1.0 https://sparkcures.com/clinical-trials/view/896/a-trial-of-tti-621-for-patients-with-hematologic-malignancies-and-selected-solid-tumors-nct02663518 2018-10-24 weeky 1.0 https://sparkcures.com/clinical-trials/view/900/study-of-the-cd38-antibody-daratumumab-in-patients-with-high-risk-mgus-and-low-risk-smoldering-multiple-myeloma-nct03236428 2019-01-15 weeky 1.0 https://sparkcures.com/clinical-trials/view/901/panobinostat-carfilzomib-and-dexamethasone-in-patients-with-relapsed-or-refractory-multiple-myeloma-nct03256045 2018-03-29 weeky 1.0 https://sparkcures.com/clinical-trials/view/903/pembrolizumab-and-radiation-therapy-in-patients-with-relapsed-or-refractory-multiple-myeloma-nct03267888 2018-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/904/study-of-actr087-in-combination-with-sea-bcma-in-subjects-with-relapsed-or-refractory-multiple-myeloma-nct03266692 2019-03-18 weeky 1.0 https://sparkcures.com/clinical-trials/view/906/study-of-bb21217-in-multiple-myeloma-nct03274219 2019-04-14 weeky 1.0 https://sparkcures.com/clinical-trials/view/907/nct03215030 2019-04-16 weeky 1.0 https://sparkcures.com/clinical-trials/view/908/dose-escalation-study-of-bfcr4350a-in-participants-with-relapsed-or-refractory-multiple-myeloma-rr-mm-nct03275103 2019-05-17 weeky 1.0 https://sparkcures.com/clinical-trials/view/912/study-of-azd5991-in-relapsed-or-refractory-haematologic-malignancies-nct03218683 2018-06-08 weeky 1.0 https://sparkcures.com/clinical-trials/view/913/p-bcma-101-tscm-car-t-cells-in-the-treatment-of-patients-with-multiple-myeloma-mm-nct03288493 2018-09-25 weeky 1.0 https://sparkcures.com/clinical-trials/view/914/aggressive-smoldering-curative-approach-evaluating-novel-therapies-and-transplant-ascent-nct03289299 2018-08-17 weeky 1.0 https://sparkcures.com/clinical-trials/view/915/a-phase-1-study-of-amg-701-in-subjects-with-multiple-myeloma-nct03287908 2019-02-22 weeky 1.0 https://sparkcures.com/clinical-trials/view/916/a-phase-12a-dose-finding-study-of-pt-112-in-patients-with-relapsed-or-refractory-multiple-myeloma-nct03288480 2018-09-18 weeky 1.0 https://sparkcures.com/clinical-trials/view/917/a-study-of-daratumumab-in-patients-with-newly-diagnosed-multiple-myeloma-nct03290950 2018-09-18 weeky 1.0 https://sparkcures.com/clinical-trials/view/919/study-of-gbr-1342-in-subjects-with-previously-treated-multiple-myeloma-nct03309111 2019-02-14 weeky 1.0 https://sparkcures.com/clinical-trials/view/920/prospective-multiple-myeloma-impact-study-prommis-nct02911571 2019-04-30 weeky 1.0 https://sparkcures.com/clinical-trials/view/981/a-study-comparing-daratumumab-velcade-bortezomib-lenalidomide-and-dexamethasone-d-vrd-with-velcade-lenalidomide-and-dexamethasone-vrd-in-participants-with-untreated-multiple-myeloma-and-for-whom-hematopoietic-stem-cell-transplant-is-not-planned-as-initial-therapy-nct03652064 2019-05-02 weeky 1.0 https://sparkcures.com/clinical-trials/view/925/an-effectiveness-and-safety-study-of-ixazomib-in-combination-with-lenalidomide-and-dexamethasone-ird-in-participants-with-multiple-myeloma-previously-receiving-a-bortezomib-based-triplet-induction-regimen-tourmaline-mm-6-nct03173092 2019-05-21 weeky 1.0 https://sparkcures.com/clinical-trials/view/926/immunotherapy-with-bcma-car-t-cells-in-treating-patients-with-bcma-positive-relapsed-or-refractory-multiple-myeloma-nct03338972 2019-05-21 weeky 1.0 https://sparkcures.com/clinical-trials/view/927/carfilzomib-revlimid-dexamethasone-elotuzumab-in-relapsedrefractory-multiple-myeloma-nct03361306 2017-12-22 weeky 1.0 https://sparkcures.com/clinical-trials/view/930/phase-1-study-of-pf-06863135-a-bcma-cd3-bispecific-antibody-in-relapse-refractory-multiple-myeloma-nct03269136 2018-11-28 weeky 1.0 https://sparkcures.com/clinical-trials/view/931/a-safety-study-of-sgn-cd48a-in-patients-with-multiple-myeloma-nct03379584 2019-03-12 weeky 1.0 https://sparkcures.com/clinical-trials/view/932/allogeneic-myeloma-gm-csf-vaccine-with-lenalidomide-compared-to-lenalidomide-alone-in-multiple-myeloma-patients-nct03376477 2018-09-07 weeky 1.0 https://sparkcures.com/clinical-trials/view/933/cmv-mva-triplex-vaccine-to-enhance-adaptive-nk-cell-reconstitution-after-autologous-hematopoietic-cell-transplantation-in-patients-with-lymphoid-malignancies-nct03383055 2017-12-28 weeky 1.0 https://sparkcures.com/clinical-trials/view/935/a-safety-pk-and-efficacy-study-of-cc-92480-in-combination-with-dexamethasone-in-subjects-with-relapsed-and-refractory-multiple-myeloma-nct03374085 2018-05-22 weeky 1.0 https://sparkcures.com/clinical-trials/view/936/a-phase-i-trial-testing-nam-expanded-haploidentical-or-mismatched-related-donor-natural-killer-nk-cells-followed-by-a-short-course-of-il-2-for-the-treatment-of-relapsedrefractory-multiple-myeloma-and-relapsedrefractory-cd20-non-hodgkin-lymphoma-nct03019666 2018-01-17 weeky 1.0 https://sparkcures.com/clinical-trials/view/938/dose-escalation-study-of-jnj-64407564-in-participants-with-relapsed-or-refractory-multiple-myeloma-nct03399799 2019-03-01 weeky 1.0 https://sparkcures.com/clinical-trials/view/939/ny-eso-1-redirected-crispr-tcrendo-and-pd1-edited-t-cells-nyce-t-cells-nct03399448 2019-04-24 weeky 1.0 https://sparkcures.com/clinical-trials/view/940/study-evaluating-the-safety-and-efficacy-of-jcarh125-in-subjects-with-relapsed-or-refractory-multiple-myeloma-evolve-nct03430011 2019-02-20 weeky 1.0 https://sparkcures.com/clinical-trials/view/941/monoclonal-antibody-based-sequential-therapy-for-deep-remission-in-multiple-myeloma-master-nct03224507 2019-04-16 weeky 1.0 https://sparkcures.com/clinical-trials/view/942/bird-vs-rd-as-initial-therapy-in-multiple-myeloma-nct02516696 2018-02-14 weeky 1.0 https://sparkcures.com/clinical-trials/view/943/study-of-cd8-anti-bcma-car-t-cells-in-patients-with-multiple-myeloma-nct03448978 2019-05-15 weeky 1.0 https://sparkcures.com/clinical-trials/view/944/a-phase-1-study-of-the-safety-and-efficacy-of-car2-anti-cd38-a2-car-t-cells-in-patients-with-relapsed-or-refractory-multiple-myeloma-nct03464916 2019-04-24 weeky 1.0 https://sparkcures.com/clinical-trials/view/945/study-of-stro-001-an-anti-cd74-antibody-drug-conjugate-in-patients-with-advanced-b-cell-malignancies-nct03424603 2019-04-14 weeky 1.0 https://sparkcures.com/clinical-trials/view/946/a-phase-12a-study-investigating-tak-079-administered-subcutaneously-in-patients-with-relapsedrefractory-multiple-myeloma-nct03439280 2018-08-15 weeky 1.0 https://sparkcures.com/clinical-trials/view/948/short-course-daratumumab-in-patients-with-multiple-myeloma-nct03490344 2019-05-21 weeky 1.0 https://sparkcures.com/clinical-trials/view/949/ixazomib-onc201-and-dexamethasone-in-relapsedrefractory-multiple-myeloma-nct03492138 2018-04-14 weeky 1.0 https://sparkcures.com/clinical-trials/view/950/study-of-melflufen-dex-with-bortezomib-or-daratumumab-in-patients-with-relapsed-or-refractory-multiple-myeloma-nct03481556 2018-06-09 weeky 1.0 https://sparkcures.com/clinical-trials/view/951/medi2228-in-subjects-with-relapsedrefractory-multiple-myeloma-nct03489525 2019-03-18 weeky 1.0 https://sparkcures.com/clinical-trials/view/952/bcma-specific-car-t-cells-combined-with-a-gamma-secretase-inhibitor-jsmd194-to-treat-relapsed-or-persistent-multiple-myeloma-nct03502577 2019-02-20 weeky 1.0 https://sparkcures.com/clinical-trials/view/954/cabozantinib-as-a-targeted-strategy-to-reverse-carfilzomib-resistance-in-refractory-multiple-myeloma-nct03201250 2019-03-18 weeky 1.0 https://sparkcures.com/clinical-trials/view/955/up-front-cart-bcma-with-or-without-hucart19-in-high-risk-multiple-myeloma-nct03549442 2019-04-21 weeky 1.0 https://sparkcures.com/clinical-trials/view/956/a-study-of-jnj-68284528-a-chimeric-antigen-receptor-t-cell-car-t-therapy-directed-against-b-cell-maturation-antigen-bcma-in-participants-with-relapsed-or-refractory-multiple-myeloma-nct03548207 2019-05-14 weeky 1.0 https://sparkcures.com/clinical-trials/view/959/an-efficacy-and-safety-study-of-bb2121-in-subjects-with-relapsed-and-refractory-multiple-myeloma-and-in-subjects-with-high-risk-multiple-myeloma-karmma-2-nct03601078 2019-04-25 weeky 1.0 https://sparkcures.com/clinical-trials/view/960/t-cells-expressing-a-novel-fully-human-anti-bcma-car-for-treating-multiple-myeloma-nct03602612 2018-09-02 weeky 1.0 https://sparkcures.com/clinical-trials/view/961/a-phase-1-study-of-sea-bcma-in-patients-with-relapsed-or-refractory-multiple-myeloma-nct03582033 2019-04-14 weeky 1.0 https://sparkcures.com/clinical-trials/view/963/study-of-srf231-in-patients-with-advanced-solid-and-hematologic-cancers-nct03512340 2018-08-29 weeky 1.0 https://sparkcures.com/clinical-trials/view/964/efficacy-and-safety-study-of-bb2121-versus-standard-triplet-regimens-in-subjects-with-relapsed-and-refractory-multiple-myeloma-karmma-3-nct03651128 2019-05-21 weeky 1.0 https://sparkcures.com/clinical-trials/view/966/study-evaluating-amg-424-in-subjects-with-multiple-myeloma-nct03445663 2019-05-02 weeky 1.0 https://sparkcures.com/clinical-trials/view/967/nct03412565 2019-05-02 weeky 1.0 https://sparkcures.com/clinical-trials/view/968/a-phase-i-study-of-autologous-car-t-cells-targeting-the-cd138-antigen-for-relapsed-or-refractory-multiple-myeloma-nct03672318 2018-10-02 weeky 1.0 https://sparkcures.com/clinical-trials/view/973/isatuximab-in-combination-with-cemiplimab-in-relapsedrefractory-multiple-myeloma-rrmm-patients-nct03194867 2018-11-28 weeky 1.0 https://sparkcures.com/clinical-trials/view/975/clinical-benefit-of-sar650984-bortezomib-lenalidomide-and-dexamethasone-combination-in-ndmm-patients-not-eligible-for-transplant-imroz-nct03319667 2018-10-05 weeky 1.0 https://sparkcures.com/clinical-trials/view/976/a-study-of-ixazomib-daratumumab-dexamethasone-idd-in-relapsed-andor-refractory-multiple-myeloma-rrmm-nct03439293 2018-10-05 weeky 1.0 https://sparkcures.com/clinical-trials/view/977/a-phase-iii-study-to-evaluate-safety-tolerability-and-clinical-activity-of-the-antibody-drug-conjugate-gsk2857916-administered-in-combination-with-lenalidomide-plus-dexamethasone-arm-a-or-bortezomib-plus-dexamethasone-arm-b-in-participants-with-relapsed-refractory-multiple-myeloma-dreamm-6-nct03544281 2019-05-15 weeky 1.0 https://sparkcures.com/clinical-trials/view/978/cs1-car-t-therapy-following-chemotherapy-in-treating-patients-with-relapsed-or-refractory-multiple-myeloma-nct03710421 2019-05-09 weeky 1.0 https://sparkcures.com/clinical-trials/view/979/predicting-progression-of-developing-myeloma-in-a-high-risk-screened-population-promise-nct03689595 2018-11-13 weeky 1.0 https://sparkcures.com/clinical-trials/view/980/dexamethasone-elotuzumab-and-pomalidomide-in-treating-patients-with-refractory-multiple-myeloma-nct03713294 2019-01-11 weeky 1.0 https://sparkcures.com/clinical-trials/view/983/myeloma-developing-regimens-using-genomics-mydrug-nct03732703 2019-05-14 weeky 1.0 https://sparkcures.com/clinical-trials/view/985/compassionate-use-individual-request-program-for-gsk2857916-in-multiple-myeloma-nct03763370 2018-12-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/986/dexamethasone-carfilzomib-nivolumab-with-reovirus-for-relapsedrefractory-multiple-myeloma-nct03605719 2019-01-04 weeky 1.0 https://sparkcures.com/clinical-trials/view/987/a-study-to-explore-the-safety-and-clinical-activity-of-gsk2857916-when-given-with-pembrolizumab-in-study-participants-with-relapsedrefractory-multiple-myeloma-dreamm-4-nct03848845 2019-05-14 weeky 1.0 https://sparkcures.com/clinical-trials/view/988/safety-tolerability-pharmacokinetics-and-efficacy-of-amg-397-in-subjects-with-multiple-myeloma-nhl-and-aml-nct03465540 2019-05-14 weeky 1.0 https://sparkcures.com/clinical-trials/view/989/cb-839-hcl-in-combination-with-carfilzomib-and-dexamethasone-in-treating-patients-with-recurrent-or-refractory-multiple-myeloma-nct03798678 2019-05-21 weeky 1.0 https://sparkcures.com/clinical-trials/view/990/assessment-of-amg-420-in-subjects-with-relapsed-andor-refractory-multiple-myeloma-nct03836053 2019-05-03 weeky 1.0 https://sparkcures.com/clinical-trials/view/992/high-dose-ascorbic-acid-for-plasma-cell-disorders-nct03602235 2019-04-19 weeky 1.0 https://sparkcures.com/clinical-trials/view/993/siltuximab-to-decrease-symptom-burden-after-autologous-stem-cell-transplantation-for-patients-with-multiple-myeloma-and-al-amyloidosis-nct03315026 2019-04-19 weeky 1.0 https://sparkcures.com/clinical-trials/view/994/a-study-of-carfilzomib-lenalidomide-dexamethasone-and-daratumumab-for-patients-with-relapsed-refractory-myeloma-with-salvage-autologous-hematopoietic-cell-transplantation-nct03556332 2019-05-02 weeky 1.0 https://sparkcures.com/clinical-trials/view/997/denosumab-for-smoldering-multiple-myeloma-nct03839459 2019-04-25 weeky 1.0 https://sparkcures.com/clinical-trials/view/999/lenalidomide-and-dexamethasone-with-or-without-daratumumab-in-treating-patients-with-high-risk-smoldering-myeloma-nct03937635 2019-05-14 weeky 1.0 https://sparkcures.com/clinical-trials/view/1001/metformin-and-nelfinavir-in-treating-patients-with-relapsed-and-or-refractory-multiple-myeloma-nct03829020 2019-05-14 weeky 1.0 https://sparkcures.com/clinical-trials/view/1002/carfilzomib-pomalidomide-and-dexamethasone-in-treating-patients-with-high-risk-multiple-myeloma-nct03756896 2019-05-17 weeky 1.0 https://sparkcures.com/clinical-trials/view/969/safety-and-efficacy-of-abi-009-nab-rapamycin-in-combination-with-pomalidomide-and-dexamethasone-for-relapsed-and-refractory-multiple-myeloma-nct03657420 2018-09-19 weeky 1.0 https://sparkcures.com/clinical-trials/view/971/a-study-of-for46-in-patients-with-relapsed-or-refractory-multiple-myeloma-rrmm-nct03650491 2018-09-20 weeky 1.0 https://sparkcures.com/clinical-trials/view/972/daratumumab-carfilzomib-lenalidomide-and-low-dose-dexamethasone-dkrd-in-newly-diagnosed-multiple-myeloma-nct03500445 2018-12-12 weeky 1.0 https://sparkcures.com/clinical-trials/view/998/a-multi-center-phase-1-open-label-dose-escalation-and-expansion-study-of-tnb-383b 2019-05-01 weeky 1.0 https://sparkcures.com/clinical-trials/view/995/2015-10-expanded-natural-killer-cells-and-elotuzumab-for-high-risk-myeloma-post-autologous-stem-cell-transplant-asct-nct03003728 2019-04-25 weeky 1.0 https://sparkcures.com/clinical-trials/view/996/daratumumab-after-stem-cell-transplant-in-treating-patients-with-multiple-myeloma-nct03346135 2019-04-25 weeky 1.0 https://sparkcures.com/clinical-trials/view/1000/daratumumab-ixazomib-dexamethasone-with-or-without-bortezomib-in-patients-with-newly-diagnosed-multiple-myeloma-derive-nct03942224 2019-05-08 weeky 1.0 https://sparkcures.com/clinical-trials/view/839/nct02899052 2018-11-01 weeky 1.0 https://sparkcures.com/clinical-trials/view/239/nct01794520 2019-03-18 weeky 1.0 https://sparkcures.com/clinical-trials/view/240/nct01794507 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/743/nct02492750 2018-05-22 weeky 1.0 https://sparkcures.com/clinical-trials/view/762/nct02569320 2017-07-28 weeky 1.0 https://sparkcures.com/clinical-trials/view/797/nct02697344 2018-11-01 weeky 1.0 https://sparkcures.com/clinical-trials/view/798/nct02700841 2017-07-27 weeky 1.0 https://sparkcures.com/clinical-trials/view/814/nct02784483 2018-01-09 weeky 1.0 https://sparkcures.com/clinical-trials/view/825/nct02851056 2019-01-11 weeky 1.0 https://sparkcures.com/clinical-trials/view/826/nct02755597 2019-03-22 weeky 1.0 https://sparkcures.com/clinical-trials/view/836/nct02903381 2017-12-22 weeky 1.0 https://sparkcures.com/clinical-trials/view/859/nct03015792 2018-10-15 weeky 1.0 https://sparkcures.com/clinical-trials/view/902 2018-09-02 weeky 1.0 https://sparkcures.com/clinical-trials/view/923/nct03314181 2019-03-22 weeky 1.0 https://sparkcures.com/clinical-trials/view/937/nct03399539 2019-01-11 weeky 1.0 https://sparkcures.com/clinical-trials/view/957/NCT03567616 2019-03-22 weeky 1.0 https://sparkcures.com/clinical-trials/view/962/nct03539744 2019-03-22 weeky 1.0 https://sparkcures.com/clinical-trials/view/970/nivolumab-and-tocilizumab-for-relapsed-hematological-malignancy-post-allogeneic-transplant-nct03588936 2019-04-16 weeky 1.0 https://sparkcures.com/clinical-trials/view/991/nct03701321 2019-04-21 weeky 1.0 https://sparkcures.com/myeloma-centers 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/region/northeast 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/region/midwest 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/region/west 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/region/southeast 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/region/southwest 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/alabama 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/alaska 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/arizona 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/arkansas 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/california 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/colorado 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/connecticut 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/delaware 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/florida 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/georgia 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/hawaii 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/idaho 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/illinois 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/indiana 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/iowa 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/kansas 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/kentucky 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/louisiana 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/maine 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/maryland 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/massachusetts 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/michigan 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/minnesota 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/mississippi 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/missouri 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/montana 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/nebraska 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/nevada 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/newhampshire 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/newjersey 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/newmexico 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/newyork 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/northcarolina 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/northdakota 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/ohio 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/oklahoma 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/oregon 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/pennsylvania 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/rhodeisland 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/southcarolina 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/southdakota 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/tennessee 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/texas 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/utah 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/vermont 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/virginia 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/washington 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/washingtondc 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/westvirginia 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/wisconsin 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/state/wyoming 2019-05-20 weeky 0.5 https://sparkcures.com/myeloma-centers/view/103/abramson-cancer-center-university-of-pennsylvania 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/2378/banner-university-medical-center-tucson-banner-health 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/15/wayne-state-university-barbara-ann-karmanos-cancer-institute 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/2247/barrett-cancer-center-university-of-cincinnati-health 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/21/baylor-charles-a-sammons-cancer-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/32/beth-israel-deaconess-medical-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/60/billings-clinic-cancer-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/2/chao-family-comprehensive-cancer-center-university-of-california-irvine 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/13/city-of-hope-comprehensive-cancer-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/100/cleveland-clinic-taussig-cancer-institute 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/27/colorado-blood-cancer-institute-presbyterian-st-lukes-medical-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/2437/cotton-oneil-cancer-center-stormont-vail-health 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/24/dana-farber-cancer-institute 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/62/dartmouth-hitchcock-medical-center-norris-cotton-cancer-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/81/duke-cancer-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/399/fox-chase-cancer-center-temple-health 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/334/fred-hutchinson-cancer-research-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/654/georgetown-lombardi-comprehensive-cancer-center-georgetown-university 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/510/harold-alfond-center-for-cancer-care 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/74/columbia-university-medical-center-herbert-irving-comprehensive-cancer-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/605/hillman-cancer-center-university-of-pittsburgh-medical-center-upmc 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/458/holden-comprehensive-cancer-center-university-of-iowa 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/101/medical-university-of-south-carolina-hollings-cancer-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/339/huntsman-cancer-institute-university-of-utah 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/385/indiana-university-simon-cancer-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/414/james-r-berenson-md-inc 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/65/john-theurer-cancer-center-hackensack-meridian-health 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/80/levine-cancer-institute 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/105/university-of-minnesota-masonic-cancer-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/31/massachusetts-general-hospital 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/396/mayo-clinic-jacksonville 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/6/mayo-clinic-rochester 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/1/mayo-clinic-scottsdale 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/7/md-anderson-cancer-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/353/medical-college-wisconsin-froedtert-hospital 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/75/memorial-sloan-kettering 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/29/moffitt-cancer-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/43/moores-cancer-center-university-of-california-san-diego-health 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/16/mount-sinai-hospital-tisch-cancer-institute 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/431/national-institutes-of-health-nih 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/17/new-york-university-langone-medical-center-laura-and-isaac-perlmutter-cancer-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/86/oregon-health-and-science-university-knight-cancer-institute 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/627/penn-state-hershey-medical-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/580/robert-h-lurie-comprehensive-cancer-center-northwestern-university 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/47/rocky-mountain-cancer-centers-denver-midtown 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/2462/roger-williams-medical-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/102/roswell-park-cancer-institute 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/1254/rutland-regional-medical-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/22/sarah-cannon 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/346/university-of-florida-health-shands-hospital 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/437/sidney-kimmel-comprehensive-cancer-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/39/siteman-cancer-center-washington-university 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/323/stanford-cancer-institute 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/1567/swedish-cancer-institute 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/578/sylvester-comprehensive-cancer-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/85/the-ohio-state-university-comprehensive-cancer-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/89/the-university-of-texas-southwestern-medical-center-harold-c-simmons-comprehensive-cancer-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/443/thomas-jefferson-university-sidney-kimmel-medical-college 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/321/university-of-alabama-at-birmingham-comprehensive-cancer-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/582/ucla-jonsson-comprehensive-cancer-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/1202/university-of-kentucky-markey-cancer-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/331/university-of-north-carolina-lineberger-comprehensive-cancer-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/322/university-of-arizona-comprehensive-cancer-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/108/university-of-arkansas-for-medical-sciences 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/570/university-of-california-davis-comprehensive-cancer-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/46/university-of-california-san-francisco 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/4/university-of-chicago-medicine 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/2164/university-of-colorado-health-poudre-valley-hospital 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/184/university-of-kansas-cancer-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/23/university-of-maryland-medical-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/5/university-of-michigan-comprehensive-cancer-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/61/university-of-nebraska-medical-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/106/uw-carbone-cancer-center-university-of-wisconsin-health 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/20/vanderbilt-ingram-cancer-center 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/94/virginia-cancer-specialists 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/332/wake-forest-baptist-health-wake-forest-university 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/76/weill-cornell-medicine 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/286/west-virginia-university 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/10/winship-cancer-institute-of-emory-university 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-centers/view/9/yale-cancer-center-smilow-cancer-hospital-at-yale-new-haven 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-treatments 2019-05-20 weeky 0.5 https://sparkcures.com/treatments/view/1/bortezomib 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/2/carfilzomib 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/3/lenalidomide 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/5/pomalidomide 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/6/thalidomide 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/21/autologous-transplant 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/22/allogeneic-transplant 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/24/venetoclax 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/30/panobinostat 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/31/ibrutinib 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/36/ixazomib 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/37/elotuzumab 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/50/trametinib 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/51/daratumumab 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/69/cabozantinib 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/79/cetuximab 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/82/pneumococcal-13-valent-conjugate-vaccine 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/93/measles-virus 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/94/isatuximab 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/99/nivolumab 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/103/pvx-410 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/113/dabrafenib 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/120/pembrolizumab 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/127/anti-bcma-car-t-cells 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/128/selinexor 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/130/gsk2857916 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/134/denosumab 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/148/temsirolimus 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/153/atezolizumab 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/192/survaxm 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/219/cart-bcma 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/222/clr-131 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/225/tinostamustine 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/228/incb053914 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/229/onc201 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/232/durvalumab 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/236/bb2121 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/243/trivalent-influenza-vaccine 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/254/yeliva 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/257/survivin-vaccine 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/258/natural-killer-cells 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/263/amg176 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/264/melflufen 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/268/lintuzumab-ac-225 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/274/gsk525762 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/275/cc-220 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/277/ro6870810 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/278/medi7247 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/279/jnj-64007957 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/283/tew-7197 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/284/tti-621 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/288/sea-bcma 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/290/bfcr4350a 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/291/bb21217 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/292/azd5991 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/293/p-bcma-101 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/294/amg701 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/302/pf-06863135 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/303/sgn-cd48a 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/306/jnj-64407564 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/308/jcarh125 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/310/tak-079 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/311/cc-93269 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/312/medi2228 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/314/car2-anti-cd38-a2-car-t-cells 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/318/amg420 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/321/descartes-08 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/323/nelfinavir 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/325/abemacicliba 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/328/jnj-68284528 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/330/amg-397 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/332/hucart19 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/333/bcma-specific-car-expressing-t-lymphocytes 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/334/cs1-car-t-therapy 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/335/car138-t-cells 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/336/fcarh143 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/338/ucartcs1 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/339/allo-715 2019-05-20 weeky 0.8 https://sparkcures.com/treatments/view/340/tnb-383b 2019-05-20 weeky 0.8 https://sparkcures.com/myeloma-tags 2019-05-20 weeky 0.5 https://sparkcures.com/tags/view/1000/car-t-cell 2019-05-20 weeky 0.7 https://sparkcures.com/tags/view/1003/monoclonal-antibody 2019-05-20 weeky 0.7 https://sparkcures.com/tags/view/1005/compassionate-use 2019-05-20 weeky 0.7 https://sparkcures.com/tags/view/1006/selective-inhibition-of-nuclear-export 2019-05-20 weeky 0.7 https://sparkcures.com/tags/view/1008/proteasome-inhibitor 2019-05-20 weeky 0.7 https://sparkcures.com/tags/view/1009 2019-05-20 weeky 0.7 https://sparkcures.com/tags/view/1010/b-cell-maturation-antigen-bcma 2019-05-20 weeky 0.7 https://sparkcures.com/tags/view/1011/participate-from-home 2019-05-20 weeky 0.7 https://sparkcures.com/tags/view/1012/checkpoint-inhibitor 2019-05-20 weeky 0.7 https://sparkcures.com/tags/view/1014/vaccine 2019-05-20 weeky 0.7 https://sparkcures.com/tags/view/1015/programmed-death-receptor-1-pd-1 2019-05-20 weeky 0.7 https://sparkcures.com/tags/view/1017/slamf7-cs1-cd319 2019-05-20 weeky 0.7 https://sparkcures.com/tags/view/1018/cd138 2019-05-20 weeky 0.7 https://sparkcures.com/tags/view/1021/stem-cell-transplant 2019-05-20 weeky 0.7 https://sparkcures.com/tags/view/1023/bromodomain-and-extra-terminal-protein-bet-inhibitor 2019-05-20 weeky 0.7 https://sparkcures.com/tags/view/1024/antibody-drug-conjugate 2019-05-20 weeky 0.7 https://sparkcures.com/tags/view/1025/bcl-2-inhibitor 2019-05-20 weeky 0.7 https://sparkcures.com/tags/view/1028/cd48 2019-05-20 weeky 0.7 https://sparkcures.com/tags/view/1032/histone-deacetylase-hdac-inhibitor 2019-05-20 weeky 0.7 https://sparkcures.com/tags/view/1039/cd33 2019-05-20 weeky 0.7 https://sparkcures.com/tags/view/1040/bispecific-t-cell-engager-bite 2019-05-20 weeky 0.7 https://sparkcures.com/tags/view/1047/bispecific-antibody 2019-05-20 weeky 0.7 https://sparkcures.com/tags/view/1049/gprc5d 2019-05-20 weeky 0.7 https://sparkcures.com/tags/view/1052/nci-cancer-center 2019-05-20 weeky 0.7 https://sparkcures.com/tags/view/1057/cd19 2019-05-20 weeky 0.7